echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Big variety of 5 billion injections, Beite, Poinsettia...4 reviews on the same day

    Big variety of 5 billion injections, Beite, Poinsettia...4 reviews on the same day

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News, May 25th.
    Recently, the NMPA official website released the latest batch of drug approval information.
    Another enterprise of omeprazole sodium for injection passed the consistency evaluation.
    Hainan Beite, Poinsettia, Kelun, and Sialon Pharmaceutical Co.
    , Ltd.
    received the approval on the same day.
    Approved, the product has been evaluated by 7 companies so far.
    The fourth batch of countries adopted pantoprazole sodium for injection, and the forthcoming fifth batch will have two more PPI injections.
     
    Figure 1: The latest review of enterprises with Omeprazole Sodium for Injection
    Source: NMPA official website
     
    Omeprazole is the world's first approved proton pump inhibitor.
    Compared with other similar drugs, it has the advantages of wide indications, high safety, and obvious pharmacoeconomic advantages.
    Omeprazole sodium for injection is mainly used for ulcers.
    Bleeding, acute gastric mucosal injury, prevention of severe diseases (such as cerebral hemorrhage, severe trauma, etc.
    ) stress state and upper gastrointestinal bleeding caused by gastric surgery.
    According to data from Menet.
    com, the sales of omeprazole sodium for injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will drop to 5 billion in 2020 due to the epidemic.
    Yuan level, but still occupy the TOP1 throne of injection products for peptic ulcer treatment.
     
      Figure 2: The share of TOP5 companies in Omeprazole Sodium for Injection in 2020
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      In 2020, in China's public medical institutions, Osaikon will occupy more than 40% of the market share of Omeprazole Sodium for injection.
    At present, the company's two specifications have been reviewed; TOP2 is occupied by the original research pharmaceutical company AstraZeneca, TOP3, TO4 , Supplementary applications for consistency evaluation of TOP5 pharmaceutical companies are under review and approval.
     
      As of now, in addition to Omeprazole Sodium for injection, the companies that have reviewed omeprazole sodium include Shandong Luoxin Pharmaceutical, Shandong New Times Pharmaceutical, Guangzhou Poinsettia Pharmaceutical, Hainan Beite Pharmaceutical, Hunan Kelun Pharmaceutical, and Hunan Saican.
    Long Pharmaceutical has a total of 7 companies.
     
      Table 1: Sales and national procurement of PPI injections
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      At present, among the best-selling PPI injections in public medical institutions in China, pantoprazole, esomeprazole (esomeprazole) and lansoprazole have been included in the national procurement, and there are no companies for rabeprazole injections.
    According to reviews, ilaprazole is Livzon’s exclusive new drug.
     
      Source: NMPA official website, Mi Nei.
    com database
      Medical Network News, May 25th.
    Recently, the NMPA official website released the latest batch of drug approval information.
    Another enterprise of omeprazole sodium for injection passed the consistency evaluation.
    Hainan Beite, Poinsettia, Kelun, and Sialon Pharmaceutical Co.
    , Ltd.
    received the approval on the same day.
    Approved, the product has been evaluated by 7 companies so far.
    The fourth batch of countries adopted pantoprazole sodium for injection, and the forthcoming fifth batch will have two more PPI injections.
     
      Figure 1: The latest review of enterprises with Omeprazole Sodium for Injection
      Source: NMPA official website
     
      Omeprazole is the world's first approved proton pump inhibitor.
    Compared with other similar drugs, it has the advantages of wide indications, high safety, and obvious pharmacoeconomic advantages.
    Omeprazole sodium for injection is mainly used for ulcers.
    Bleeding, acute gastric mucosal injury, prevention of severe diseases (such as cerebral hemorrhage, severe trauma, etc.
    ) stress state and upper gastrointestinal bleeding caused by gastric surgery.
    According to data from Menet.
    com, the sales of omeprazole sodium for injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will drop to 5 billion in 2020 due to the epidemic.
    Yuan level, but still occupy the TOP1 throne of injection products for peptic ulcer treatment.
     
      Figure 2: The share of TOP5 companies in Omeprazole Sodium for Injection in 2020
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      In 2020, in China's public medical institutions, Osaikon will occupy more than 40% of the market share of Omeprazole Sodium for injection.
    At present, the company's two specifications have been reviewed; TOP2 is occupied by the original research pharmaceutical company AstraZeneca, TOP3, TO4 , Supplementary applications for consistency evaluation of TOP5 pharmaceutical companies are under review and approval.
     
      As of now, in addition to Omeprazole Sodium for injection, the companies that have reviewed omeprazole sodium include Shandong Luoxin Pharmaceutical, Shandong New Times Pharmaceutical, Guangzhou Poinsettia Pharmaceutical, Hainan Beite Pharmaceutical, Hunan Kelun Pharmaceutical, and Hunan Saican.
    Long Pharmaceutical has a total of 7 companies.
     
      Table 1: Sales and national procurement of PPI injections
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      At present, among the best-selling PPI injections in public medical institutions in China, pantoprazole, esomeprazole (esomeprazole) and lansoprazole have been included in the national procurement, and there are no companies for rabeprazole injections.
    According to reviews, ilaprazole is Livzon’s exclusive new drug.
     
      Source: NMPA official website, Mi Nei.
    com database
      Medical Network News, May 25th.
    Recently, the NMPA official website released the latest batch of drug approval information.
    Another enterprise of omeprazole sodium for injection passed the consistency evaluation.
    Hainan Beite, Poinsettia, Kelun, and Sialon Pharmaceutical Co.
    , Ltd.
    received the approval on the same day.
    Approved, the product has been evaluated by 7 companies so far.
    The fourth batch of countries adopted pantoprazole sodium for injection, and the forthcoming fifth batch will have two more PPI injections.
     
      Figure 1: The latest review of enterprises with Omeprazole Sodium for Injection
      Source: NMPA official website
     
      Omeprazole is the world's first approved proton pump inhibitor.
    Compared with other similar drugs, it has the advantages of wide indications, high safety, and obvious pharmacoeconomic advantages.
    Omeprazole sodium for injection is mainly used for ulcers.
    Bleeding, acute gastric mucosal injury, prevention of severe diseases (such as cerebral hemorrhage, severe trauma, etc.
    ) stress state and upper gastrointestinal bleeding caused by gastric surgery.
    According to data from Menet.
    com, the sales of omeprazole sodium for injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will drop to 5 billion in 2020 due to the epidemic.
    Yuan level, but still occupy the TOP1 throne of injection products for peptic ulcer treatment.
    Disease disease disease hospital hospital hospital
     
      Figure 2: The share of TOP5 companies in Omeprazole Sodium for Injection in 2020
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      In 2020, in China's public medical institutions, Osaikon will occupy more than 40% of the market share of Omeprazole Sodium for injection.
    At present, the company's two specifications have been reviewed; TOP2 is occupied by the original research pharmaceutical company AstraZeneca, TOP3, TO4 , Supplementary applications for consistency evaluation of TOP5 pharmaceutical companies are under review and approval.
     
      As of now, in addition to Omeprazole Sodium for injection, the companies that have reviewed omeprazole sodium include Shandong Luoxin Pharmaceutical, Shandong New Times Pharmaceutical, Guangzhou Poinsettia Pharmaceutical, Hainan Beite Pharmaceutical, Hunan Kelun Pharmaceutical, and Hunan Saican.
    Long Pharmaceutical has a total of 7 companies.
    Enterprise business enterprise
     
      Table 1: Sales and national procurement of PPI injections
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      At present, among the best-selling PPI injections in public medical institutions in China, pantoprazole, esomeprazole (esomeprazole) and lansoprazole have been included in the national procurement, and there are no companies for rabeprazole injections.
    According to reviews, ilaprazole is Livzon’s exclusive new drug.
     
      Source: NMPA official website, Mi Nei.
    com database
      
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.